Cogent Biosciences Inc

Market Cap

$6B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$31.16-$3.58 (-10.31%)

Jun 8, 2026

52W High $42.1152W Low $6.90

Company Details

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor...

CEO

—

IPO Date

Mar 29, 2018

Website

www.cogentbio.com

Key Metrics TTM

Revenue

-100.0% YoY

Net Income

-$354M

EPS (Diluted)

Free Cash Flow

-$286M

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Earnings Reports

Q1 2026

May 5, 2026

FY 2025

Feb 17, 2026

Q4 2025

Feb 17, 2026

$0-100.0%

Q3 2025

Nov 7, 2025

Q2 2025

Aug 5, 2025

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee